Payment overview · 2025
General Payments
$344.43
13 reported records · 7 companies
Healthcare provider profile · identity verified
Jose Luis Boggio, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ERIE, PA · NPI 1851490577
Verified facts
What the public records show
CMS Open Payments records show Jose Luis Boggio, MD received $344.43 in general payments during 2025 across 13 reported records.
GlaxoSmithKline, LLC. accounted for 44.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $154.65 | 44.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $93.10 | 27.0% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$23.16 | 6.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.71 | 6.6% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.91 | 5.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.84 | 4.9% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $14.06 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $344.43 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $73.43 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.66 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.71 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 466 | 166 |
| Atorvastatin Calcium | Atorvastatin Calcium | 465 | 125 |
| Metformin Hcl | Metformin Hcl | 333 | 105 |
| Lisinopril | Lisinopril | 269 | 99 |
| Omeprazole | Omeprazole | 233 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 221 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 195 | 64 |
| Gabapentin | Gabapentin | 191 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 183 | 52 |
| Losartan Potassium | Losartan Potassium | 157 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 40 |
| Furosemide | Furosemide | 113 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 30 |
| Glimepiride | Glimepiride | 105 | 35 |
| Trazodone Hcl | Trazodone Hcl | 97 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 96 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 19 |
| Famotidine | Famotidine | 71 | 21 |
| Ibuprofen | Ibuprofen | 71 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 61 | 20 |
| Sertraline Hcl | Sertraline Hcl | 61 | 17 |
| Simvastatin | Simvastatin | 61 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 20 |
| Montelukast Sodium | Montelukast Sodium | 57 | 21 |
| Buspirone Hcl | Buspirone Hcl | 56 | suppressed |
| Levetiracetam | Levetiracetam | 56 | suppressed |
| Carvedilol | Carvedilol | 55 | 20 |
| Atenolol | Atenolol | 54 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 22 |
| Januvia | Sitagliptin Phosphate | 53 | 14 |
| Allopurinol | Allopurinol | 48 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 46 | suppressed |
| Naproxen | Naproxen | 46 | 15 |
| Enalapril Maleate | Enalapril Maleate | 45 | suppressed |
| Finasteride | Finasteride | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 16 |
| Olanzapine | Olanzapine | 45 | suppressed |
| Glipizide | Glipizide | 40 | 11 |
| Risperidone | Risperidone | 40 | 12 |
| Amoxicillin | Amoxicillin | 39 | 35 |
| Potassium Chloride | Potassium Chloride | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Eliquis | Apixaban | 35 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Ketoconazole | Ketoconazole | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 29 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Sotalol | Sotalol Hcl | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Prednisone | Prednisone | 21 | 16 |
| Latanoprost | Latanoprost | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $344.43 · 13 records | GlaxoSmithKline, LLC. | AREXVY, Cologuard Collection Kit, INGREZZA, ImmunoCAP, MINIMED 780G, PENMENVY, QULIPTA, SHINGRIX, TZIELD, UBRELVY, VRAYLAR | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error